ArticleInfectious diseases and therapy2026
Detection of a Nirsevimab-Resistant RSV-B Variant (F:K68Q) in an Adult with Severe Infection.
Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06197152 (Identification and Clinical Validation of Biomarkers Associated With Clinical Severity in Adults Infected With Respiratory Syncytial Virus), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Identification and Clinical Validation of Biomarkers Associated With Clinical Severity in Adults Infected With Respiratory Syncytial Virus
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionRespiratory syncytial virus (RSV) is recognized as a major cause of severe disease in adults, particularly those having cardiorespiratory comorbidities or immunosuppression. The recent deployment of monoclonal antibodies targeting the prefusion F protein could be used in the future to prevent RSV-associated hospitalization and critical illness in immunocompromised adult patients.
methodsThis report is part of the ongoing ARF-RSV study (NCT06197152), a prospective, multicenter observational cohort.
resultsWe report on the case of a 64-year-old man with a previous medical history of aggressive mantle cell lymphoma under active treatment who was admitted to the intensive care unit for severe sepsis in the setting of febrile aplasia. Clinical evolution was rapidly favorable, with resolution of hemodynamic failure within a few days. Two nasopharyngeal samples collected 7 days apart were positive for RSV-B. Genetic analysis identified a strain belonging to lineage B.D.E.1, with both samples harboring a dominant F:K68Q substitution in the fusion protein. In the first sample, the mean depth of coverage was over 180× and the F:K68Q substitution was detected at an allele frequency of 99%. In the second sample, collected 7 days later, the mean depth of coverage was 170×, with the same substitution detected with an allele frequency of 97%, consistent with persistence as a dominant variant over time. This substitution has been previously associated with high-level resistance to nirsevimab. More generally, F:K68Q appears to be rare among circulating RSV-B strains based on available global sequence surveillance data (GISAID). Its detection in a monoclonal antibody-naïve patient reinforces the hypothesis that this substitution may circulate independently of nirsevimab exposure.
conclusionThe persistence of a resistant RSV variant in a patient who was immunocompromised without prior exposure to nirsevimab suggests that such variants may circulate and be transmitted. In this context, RSV vaccination of patients who are immunocompromised may not only provide individual protection but also help limit the dissemination of resistant strains.
Indexed as
Identifiers
42734717What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.